Patient characteristics
. | Acyclovir . | Placebo . |
|---|---|---|
| No. patients | 38 | 39 |
| Mean age at transplantation, y (range) | 29 (10-47) | 32 (14-65) |
| Sex, no. (%) | ||
| Male | 16 (42.1) | 21 (53.8) |
| Female | 22 (57.3) | 18 (46.2) |
| Race, no. (%) | ||
| Caucasian | 36 (94.7) | 37 (94.9) |
| Underlying diseases, no. (%) | ||
| Acute leukemia | 10 (26.3) | 17 (43.6) |
| Chronic leukemia | 20 (52.7) | 17 (43.6) |
| Lymphoma | 4 (10.5) | 2 (5.1) |
| Aplastic anemia | 4 (10.5) | 1 (2.6) |
| Other | 0 (0) | 2 (5.1) |
| Donor type, no. (%) | ||
| HLA matched, related | 30 (78.9) | 31 (79.5) |
| HLA mismatched, related | 5 (13.2) | 7 (17.9) |
| HLA matched, unrelated | 3 (7.9) | 1 (2.6) |
| Acute GVHD, grade 2-4, at randomization, no. (%) | 15 (39.5) | 13 (33.3) |
| Median time of randomization, d (range) | 59 (10-91) | 62 (16-83) |
| Median start time of study drug, d (range) | 63 (31-98) | 63 (29-101) |
| Relapse of underlying disease during first 3 y, no. (%) | 17 (45) | 16 (41) |
| Survival at 1 y after transplantation, no. (%) | 32 (84.2) | 26 (67) |
. | Acyclovir . | Placebo . |
|---|---|---|
| No. patients | 38 | 39 |
| Mean age at transplantation, y (range) | 29 (10-47) | 32 (14-65) |
| Sex, no. (%) | ||
| Male | 16 (42.1) | 21 (53.8) |
| Female | 22 (57.3) | 18 (46.2) |
| Race, no. (%) | ||
| Caucasian | 36 (94.7) | 37 (94.9) |
| Underlying diseases, no. (%) | ||
| Acute leukemia | 10 (26.3) | 17 (43.6) |
| Chronic leukemia | 20 (52.7) | 17 (43.6) |
| Lymphoma | 4 (10.5) | 2 (5.1) |
| Aplastic anemia | 4 (10.5) | 1 (2.6) |
| Other | 0 (0) | 2 (5.1) |
| Donor type, no. (%) | ||
| HLA matched, related | 30 (78.9) | 31 (79.5) |
| HLA mismatched, related | 5 (13.2) | 7 (17.9) |
| HLA matched, unrelated | 3 (7.9) | 1 (2.6) |
| Acute GVHD, grade 2-4, at randomization, no. (%) | 15 (39.5) | 13 (33.3) |
| Median time of randomization, d (range) | 59 (10-91) | 62 (16-83) |
| Median start time of study drug, d (range) | 63 (31-98) | 63 (29-101) |
| Relapse of underlying disease during first 3 y, no. (%) | 17 (45) | 16 (41) |
| Survival at 1 y after transplantation, no. (%) | 32 (84.2) | 26 (67) |